Healthcare Services

Chronic Myeloid Leukemia (CML) Treatment Market Outlook 2026–2030 Exploring New Business Opportunities

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Chronic Myeloid Leukemia (CML) Treatment Market During 2026–2030?

The chronic myeloid leukemia (cml) treatment market size has seen robust growth in recent years. This market is set to expand from $8.64 billion in 2025 to $9.23 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. The historical growth in this sector is attributable to improved diagnostic accuracy for hematological cancers, wider availability of first-generation tkis, increased awareness of cml, expansion of oncology treatment centers, and improved patient survival rates.

The chronic myeloid leukemia (cml) treatment market size is projected to experience robust expansion in the upcoming years. It is forecasted to reach $12.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. This expansion during the forecast period can be attributed to the escalating development of novel targeted agents, the rising adoption of combination therapies, the enlargement of precision oncology programs, a growing focus on patient adherence to treatment, and increasing investments in cancer research. Major developments expected within this timeframe include the increasing integration of targeted therapy regimens, the rising use of next-generation TKI drugs, an intensified concentration on molecular diagnostics, the broadening of personalized treatment protocols, and a strengthened commitment to long-term disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12084&type=smp

Which Economic Or Industry Drivers Are Impacting The Chronic Myeloid Leukemia (CML) Treatment Market?

The escalating occurrence and widespread presence of the chronic myeloid leukemia (CML) population are projected to fuel the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a form of cancer that impacts the bone marrow and blood. It is distinguished by the excessive production of immature white blood cells referred to as myeloid cells. Chronic myeloid leukemia (CML) treatment aims to slow the disease’s progression and prevent it from advancing to a critical stage. For instance, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing physicians of all oncology sub-specialties, in the United States, in 2023, around 35,730 persons (19,860 men and 15,870 women) are anticipated to receive a multiple myeloma diagnosis and 12,590 deaths from this illness are anticipated in 2023 (7,000 males and 5,590 women). Therefore, the increasing incidence and prevalence of the chronic myeloid leukemia (CML) population are driving the growth of the chronic myeloid leukemia (CML) treatment market going forward.

How Are The Various Segments Of The Chronic Myeloid Leukemia (CML) Treatment Market Categorized?

The chronic myeloid leukemia (cml) treatment market covered in this report is segmented –

1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant

2) By Drug Type: Tyrosine Kinase Inhibitors, Antimetabolites, Other Drug Types

3) By Application: Hospitals, Clinic, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCR-ABL Inhibitors, Monoclonal Antibody Therapy, Signal Transduction Inhibitors

2) By Chemotherapy: Alkylating Agents, Antimetabolites, Anthracyclines, Combination Chemotherapy Regimens

3) By Radiation Therapy: External Beam Radiation Therapy, Total Body Irradiation, Radioimmunotherapy

4) By Splenectomy: Partial Splenectomy, Total Splenectomy

5) By Stem Cell Transplant: Allogeneic Hematopoietic Stem Cell Transplant, Autologous Stem Cell Transplant

What Key Trends Are Influencing The Development Of The Chronic Myeloid Leukemia (CML) Treatment Market?

Leading entities in the chronic myeloid leukemia (CML) treatment sector are strategically focusing on forming partnerships and collaborations to broaden their product portfolios, hasten commercialization, and expand their geographic reach. Such alliances empower biotechnology companies to tap into specialized expertise in market access, regulatory guidance, and oncology commercialization, thereby delivering innovative therapies to patients more efficiently. For instance, in February 2023, Xspray Pharma, a biotechnology firm based in Sweden, partnered with EVERSANA, a US-based life sciences commercialization company, to facilitate the U.S. launch and commercialization of its product Dasynoc (XS004) for treating chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). Dasynoc, representing a new and distinct therapeutic option awaiting FDA approval and legal conditions, is anticipated to enter the $3.5 billion U.S. market for tyrosine kinase inhibitors. Through this specific partnership, Xspray Pharma will gain entry to EVERSANA’s dedicated oncology-focused commercialization team, allowing for a customized and effective market entry strategy. With a planned launch in the second half of 2023, Dasynoc is expected to considerably improve treatment options for patients afflicted with CML and ALL in the United States.

Which Major Firms Influence Developments In The Chronic Myeloid Leukemia (CML) Treatment Market?

Major companies operating in the chronic myeloid leukemia (cml) treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Orca Bio, Bio-Path Holdings Inc.

Read the full chronic myeloid leukemia (cml) treatment market report here:

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

What Are The Top-Performing Regions Within The Chronic Myeloid Leukemia (CML) Treatment Market?

North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2025. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chronic Myeloid Leukemia (CML) Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12084&type=smp

Browse Through More Reports Similar to the Global Chronic Myeloid Leukemia (CML) Treatment Market 2026, By The Business Research Company

Chronic Pain Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Neuropathic Pain Global Market Report

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Muscle Pain Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795